(Total Views: 586)
Posted On: 04/27/2020 4:13:46 PM
Post# of 72443
I was initially hoping to see a PR today that Brilacidin was successful in minimizing COVID-19’s viral load. After reading today’s PR the testing that will take place next week by the RBL will be much more detailed than that. IMO if this detailed testing is successful it will immediately position Brilacidin as a Phase III treatment and probable adjuvant to a combo vaccine for COVID-19. Note that beyond the validation of Brilacidin as an effective antiviral specific to this virus, that testing will include various dose and frequency testing to maximize effectiveness while minimizing toxicity. Also note the testing to explore synergistic properties with other small molecules that have antiviral activity. This upfront testing will IMO be a guideline to rapidly deploy Brilacidin with sound science backed dose and frequency confidence.
=========================================
“that continued coronavirus (COVID-19) testing of Brilacidin, the Company’s defensin-mimetic drug candidate, is scheduled to begin the week of May 4.”
“Concurrently, the Company is prioritizing Brilacidin’s clinical development by taking steps to rapidly advance Brilacidin testing in human trials, including preparations for engaging with regulatory authorities, as the research continues into the drug’s antiviral properties.”
“Proposed further research studies to be conducted at the RBL include:
Testing Brilacidin’s direct virucidal activity on SARS-CoV-2 in human lung epithelial cells (by preincubating the novel coronavirus with Brilacidin at varying concentrations and times of incubation);
Obtaining the in vitro concentration of Brilacidin that gives half-maximal response, the EC50 value, in lung epithelial cells;
Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity);
Evaluating time-to-treatment windows as a post-exposure therapeutic (by introducing Brilacidin at 4, 8, and 16 hours post-initial infection, with virus cultures carried forward up to 48 hours);
Exploring if Brilacidin has synergistic properties with other small molecules that have antiviral activity.”
=========================================
“that continued coronavirus (COVID-19) testing of Brilacidin, the Company’s defensin-mimetic drug candidate, is scheduled to begin the week of May 4.”
“Concurrently, the Company is prioritizing Brilacidin’s clinical development by taking steps to rapidly advance Brilacidin testing in human trials, including preparations for engaging with regulatory authorities, as the research continues into the drug’s antiviral properties.”
“Proposed further research studies to be conducted at the RBL include:
Testing Brilacidin’s direct virucidal activity on SARS-CoV-2 in human lung epithelial cells (by preincubating the novel coronavirus with Brilacidin at varying concentrations and times of incubation);
Obtaining the in vitro concentration of Brilacidin that gives half-maximal response, the EC50 value, in lung epithelial cells;
Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity);
Evaluating time-to-treatment windows as a post-exposure therapeutic (by introducing Brilacidin at 4, 8, and 16 hours post-initial infection, with virus cultures carried forward up to 48 hours);
Exploring if Brilacidin has synergistic properties with other small molecules that have antiviral activity.”
(12)
(1)Scroll down for more posts ▼
